Provided by Tiger Fintech (Singapore) Pte. Ltd.

IceCure Medical Ltd.

1.20
+0.02001.69%
Post-market: 1.17-0.0300-2.50%19:40 EDT
Volume:170.69K
Turnover:205.99K
Market Cap:67.88M
PE:-3.99
High:1.23
Open:1.20
Low:1.17
Close:1.18
Loading ...

Icecure Medical’s Growth Potential Highlighted by Clinical Progress and Strategic Financial Position

TIPRANKS
·
29 Mar

IceCure Medical Stock Dips Despite Positive ICESECRET Study Results

Zacks
·
28 Mar

IceCure Medical Full Year 2024 Earnings: Misses Expectations

Simply Wall St.
·
28 Mar

Icecure Medical Price Target Maintained With a $2.50/Share by HC Wainwright & Co.

Dow Jones
·
28 Mar

IceCure Medical Sees 42% Growth in ProSense® Sales Amid Awaited FDA Decision

TIPRANKS
·
27 Mar

BRIEF-Icecure Medical FY Gross Margin 44%

Reuters
·
27 Mar

Icecure Medical FY 2024 GAAP EPS $(0.30) Misses $(0.29) Estimate, Sales $3.29M Miss $3.48M Estimate

Benzinga
·
27 Mar

Icecure Medical FY Gross Margin 44%

THOMSON REUTERS
·
27 Mar

Press Release: IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense(R) Cryoablation Sales in North America

Dow Jones
·
27 Mar

BRIEF-IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate

Reuters
·
24 Mar

IceCure Medical announces interim results from ICESECRET study

TIPRANKS
·
24 Mar

Icecure's Icesecret Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate

THOMSON REUTERS
·
24 Mar

Icecure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025

THOMSON REUTERS
·
21 Mar

IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025

PR Newswire
·
21 Mar

BUZZ-IceCure Medical falls after FDA delays decision on breast cancer treatment system

Reuters
·
21 Mar

IceCure Medical Expects FDA Decision on ProSense After Q1

MT Newswires Live
·
20 Mar

IceCure Medical in discussions with FDA on marketing request for ProSense

TIPRANKS
·
20 Mar

Icecure Reports Updated Timeline and Progress With FDA Regarding Marketing Authorization for Prosense® Cryoablation in Early-Stage Breast Cancer

THOMSON REUTERS
·
20 Mar

Icecure Medical : Expects to GET FDA's Marketing Authorization Decision for Prosense After Q1 of 2025

THOMSON REUTERS
·
20 Mar

IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer

PR Newswire
·
20 Mar